DOCSLIB.ORG

The Effects of Herkinorin, the First Mu-Selective Ligand from a Salvinorin A-Derived Scaffold, in a Neuroendocrine Biomarker Assay in Nonhuman Primates

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Effects of Herkinorin, the First Mu-Selective Ligand from a Salvinorin A-Derived Scaffold, in a Neuroendocrine Biomarker Assay in Nonhuman Primates Cedarville University DigitalCommons@Cedarville Pharmacy Faculty Publications School of Pharmacy 10-2008 The ffecE ts of Herkinorin, the First mu-Selective Ligand from a Salvinorin A-Derived Scaffold, in a Neuroendocrine Biomarker Assay in Nonhuman Primates Eduardo R. Butelman Szymon Rus Denise S. Simpson Cedarville University, [email protected] Angela Wolf Thomas E. Prisinzano See next page for additional authors Follow this and additional works at: http://digitalcommons.cedarville.edu/pharmacy_publications Part of the Pharmacy and Pharmaceutical Sciences Commons Recommended Citation Butelman, E. R., Rus, S., Simpson, D. S. , Wolf, A., Prisinzano, T. E. , Mary Jeanne Kreek, (2008). The Effects of Herkinorin, the First mu-Selective Ligand from a Salvinorin A-Derived Scaffold, in a Neuroendocrine Biomarker Assay in Nonhuman Primates. Journal of Pharmacology and Experimental Therapeutics, 327, 154-160. This Article is brought to you for free and open access by DigitalCommons@Cedarville, a service of the Centennial Library. It has been accepted for inclusion in Pharmacy Faculty Publications by an authorized administrator of DigitalCommons@Cedarville. For more information, please contact [email protected]. Authors Eduardo R. Butelman, Szymon Rus, Denise S. Simpson, Angela Wolf, Thomas E. Prisinzano, and Mary Jeanne Kreek This article is available at DigitalCommons@Cedarville: http://digitalcommons.cedarville.edu/pharmacy_publications/14 0022-3565/08/3271-154–160$20.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 327, No. 1 Copyright © 2008 by The American Society for Pharmacology and Experimental Therapeutics 140079/3381513 JPET 327:154–160, 2008 Printed in U.S.A. The Effects of Herkinorin, the First ␮-Selective Ligand from a Salvinorin A-Derived Scaffold, in a Neuroendocrine Biomarker Assay in Nonhuman Primates Eduardo R. Butelman, Szymon Rus, Denise S. Simpson, Angela Wolf, Thomas E. Prisinzano, and Mary Jeanne Kreek The Rockefeller University, New York, New York (E.R.B., S.R., M.J.K.); Division of Medicinal and Natural Products Chemistry, University of Iowa, Iowa City, Iowa (D.S.S., T.E.P.); and Department of Medicinal Chemistry, University of Kansas, Lawrence, Kansas (D.S.S., A.W., T.E.P.) Downloaded from Received April 16, 2008; accepted June 30, 2008 ABSTRACT ␮ Herkinorin is the first -opioid receptor-selective ligand from effectiveness in females and revealed a fast onset after i.v. jpet.aspetjournals.org the salvinorin A diterpenoid scaffold. Herkinorin has relative administration (e.g., by 5–15 min). Antagonism experiments ␮ Ͼ ␬ Ͼ ␦ binding selectivity, and it can act as an agonist at with different doses of nalmefene (0.01 and 0.1 mg/kg) caused both ␮- and ␬-receptors, in vitro. These studies were the first dose-dependent and complete prevention of the effect of herki- in vivo evaluation of the effects of herkinorin in nonhuman norin in females. This is consistent with a principal ␮-agonist primates, using prolactin release, a neuroendocrine biomarker effect of herkinorin, with likely partial contribution by ␬-agonist assay that is responsive to both ␮- and ␬-agonists, as well as effects. The peripherally selective antagonist quaternary nal- to compounds with limited ability to cross the blood-brain trexone (1 mg/kg s.c.) caused approximately 70% reduction in barrier. In cumulative dosing studies (0.01–0.32 mg/kg i.v.), the peak effect of herkinorin (0.32 mg/kg) in females, indicating at Cedarville Univ Lib on January 25, 2013 herkinorin produced only small effects in gonadally intact males that this effect of herkinorin is prominently mediated outside the (n ϭ 4), but a more robust effect in females (n ϭ 4). Time course blood-brain barrier. studies with herkinorin (0.32 mg/kg) confirmed this greater Salvinorin A, a plant-derived hallucinogenic diterpene, is a To date, there is no information on the in vivo effects of highly selective ␬-opioid agonist, and a novel template for herkinorin in primates. The present study focuses on an semisynthetic opioid analogs (Roth et al., 2002; Prisinzano initial evaluation of the in vivo opioid agonist effects of and Rothman, 2008). One of these novel analogs is herki- herkinorin in rhesus monkeys, using a translationally vi- norin, the first salvinorin-derived compound with ␮- over able neuroendocrine biomarker assay, release of the ante- ␬-selectivity reported in the literature (Harding et al., 2005). rior pituitary hormone prolactin. Different factors render Herkinorin has approximately 8-fold selectivity for ␮- over this neuroendocrine biomarker a practical approach for ␬-receptors and approximately 98-fold selectivity for ␮- over initial evaluation of herkinorin: 1) prolactin levels are ␦-receptors in competition binding assays (Harding et al., increased by both ␮- and ␬-agonists in mammals, including ␮ 2005). Herkinorin acts as a high-efficacy agonist at both - humans (␦-agonists seem not be to be active) (Hoehe et al., ␬ Ј and -receptors in the guanosine 5 -O-(3-thio)triphosphate 1988; Ur et al., 1997; Kreek et al., 1999; Bowen et al., 2002; assay (Harding et al., 2005), with greater relative potency at Butelman et al., 2007); and 2) effects of these opioids are at ␮ -receptors. Herkinorin also displays some unique features least partially mediated by opioid receptors outside the ␮ in its interactions at the -receptor, such as decreased ago- blood-brain barrier (e.g., in particular hypothalamic nuclei) nist-induced internalization (Groer et al., 2007; Xu et al., (Merchenthaler, 1991; Butelman et al., 2004, 2008; Zheng et 2007). al., 2005), and they may therefore be used to determine the pharmacodynamic effects of compounds with limited ability This work was funded by National Institutes of Health-National Institute on Drug Abuse Grants DA017369 (to E.R.B.), DA018151 (to T.E.P.), and to cross the blood-brain barrier. DA05130 (to M.J.K.). This study presents the first direct evaluation of the phar- Article, publication date, and citation information can be found at http://jpet.aspetjournals.org. macodynamic effects of herkinorin in male and female non- doi:10.1124/jpet.108.140079. human primates, and it also investigates potential ␮-versus ABBREVIATIONS: ANOVA, analysis of variance. 154 Herkinorin Effects on a Neuroendocrine Biomarker 155 ␬-receptor effects of this novel compound, as well as activity occurred 15 min after each injection. Herkinorin was studied herein outside the blood-brain barrier. up to the largest dose that could be administered due to solubility limitations (0.32 mg/kg). Herkinorin was then compared with salvi- norin A (its structurally related parent compound, a selective ␬-ag- Materials and Methods onist) and loperamide (a peripherally selective ␮-agonist), under Subjects similar conditions. A vehicle control study was also carried out, with four consecutive vehicle injections under identical timing conditions. Four captive-bred male and four female rhesus monkeys (Macaca Time Course Procedure. After baseline sample collection, a mulatta; age range, approximately 8–12 years; weight range, 7.0– single agonist dose (e.g., of herkinorin) was administered i.v., fol- 12.5 kg) were used. All subjects were gonadally intact. Unless oth- lowed by sampling at 5, 15, 30, 60, 90, and 120 min after adminis- ϭ erwise stated, each study was carried out with an n 4 of either tration. In antagonism experiments, a single dose of antagonist (s.c. males or females. Females were studied in the follicular phase, nalmefene or quaternary naltrexone) was administered 30 min be- estimated as days 1 to 12 from the onset of visible menses. Monkeys fore an agonist, followed by testing as described above. In these were singly housed in colony rooms maintained at 20 to 22°C, with antagonism experiments, a single sample was also taken 20 min controlled humidity and a 12:12-h light/dark cycle (lights on at 7:00 after administration of the antagonist alone (i.e., during the pre- AM). Monkeys were fed approximately 12 jumbo primate chow bis- treatment period). cuits, adjusted individually (PMI Feeds, Richmond, VA). Subjects also received appetitive treats, and multivitamins plus iron. An Design environmental enrichment plan was in place (e.g., music and videos). Water was freely available in home cages, via a waterspout. Cumulative Dose-Effect Curve Studies. Cumulative dose-ef- Downloaded from Subjects had complex history of pharmacological exposure (pri- fect curve studies were carried out in males and females for herki- marily opioid), but they had no history of any chronic or high- norin (0.01–0.32 mg/kg i.v.) compared with repeated vehicle injec- frequency exposure to any agent. Consecutive experiments in the tion, for control purposes. The effects of loperamide [0.01–0.32 mg/kg same subject were separated by at least 72 h; the order of experi- (males and females)] and salvinorin A [0.001–0.032 mg/kg (males) ments was unsystematic among subjects. All studies were carried and 0.00032–0.01 mg/kg (females), based on prior studies; Butelman et al., 2007, 2008] were also studied under identical cumulative out over the course of several months while all subjects were in jpet.aspetjournals.org stable colony rooms. Studies were reviewed by the Rockefeller Uni- dosing procedures. versity Animal Care and Use Committee, in accordance with the Time Course Studies. The time course effects of herkinorin were Guide for the Care and Use of Animals (National Academies Press; studied in male subjects, at the largest dose that could be adminis- Washington, DC, 1996). tered, as limited by solubility (0.32 mg/kg i.v., compared with vehicle i.v.). This was followed by a similar determination of the effects of Procedure for Neuroendocrine Experiments this dose in females. Because males demonstrated only a small effect of herkinorin up Chair-trained monkeys were tested after repeated exposure to the to the largest dose that could be studied, antagonism experiments at Cedarville Univ Lib on January 25, 2013 experimental situation. Monkeys were chaired and transferred to described below were only carried out in females.
Load more

Recommended publications
  • INVESTIGATION of NATURAL PRODUCT SCAFFOLDS for the DEVELOPMENT of OPIOID RECEPTOR LIGANDS by Katherine M
    INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS By Katherine M. Prevatt-Smith Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. _________________________________ Chairperson: Dr. Thomas E. Prisinzano _________________________________ Dr. Brian S. J. Blagg _________________________________ Dr. Michael F. Rafferty _________________________________ Dr. Paul R. Hanson _________________________________ Dr. Susan M. Lunte Date Defended: July 18, 2012 The Dissertation Committee for Katherine M. Prevatt-Smith certifies that this is the approved version of the following dissertation: INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS _________________________________ Chairperson: Dr. Thomas E. Prisinzano Date approved: July 18, 2012 ii ABSTRACT Kappa opioid (KOP) receptors have been suggested as an alternative target to the mu opioid (MOP) receptor for the treatment of pain because KOP activation is associated with fewer negative side-effects (respiratory depression, constipation, tolerance, and dependence). The KOP receptor has also been implicated in several abuse-related effects in the central nervous system (CNS). KOP ligands have been investigated as pharmacotherapies for drug abuse; KOP agonists have been shown to modulate dopamine concentrations in the CNS as well as attenuate the self-administration of cocaine in a variety of species, and KOP antagonists have potential in the treatment of relapse. One drawback of current opioid ligand investigation is that many compounds are based on the morphine scaffold and thus have similar properties, both positive and negative, to the parent molecule. Thus there is increasing need to discover new chemical scaffolds with opioid receptor activity.
    [Show full text]
  • Eluxadoline: a Treatment for IBS with Diarrhoea in Adults
    ■ NEW PRODUCT Eluxadoline: a treatment for IBS with diarrhoea in adults STEVE CHAPLIN Eluxadoline (Truberzi) KEY POINTS is an oral mixed opioid- receptor agonist/ ■ Eluxadoline is an opioid-receptor agonist/antagonist with low systemic absorption antagonist licensed for ■ It is licensed for the treatment of irritable bowel syndrome with diarrhoea in the treatment of irritable adults and is recommended by NICE as a second-line agent bowel syndrome with ■ The recommended dosage is 75–100mg orally twice daily diarrhoea in adults. ■ In clinical trials, response rates were 27%–31% with eluxadoline and 19.5% with placebo after 26 weeks’ treatment This article examines its ■ Common adverse effects include constipation, nausea and abdominal pain properties, efficacy in ■ Pancreatitis and sphincter of Oddi spasm were uncommon adverse events clinical trials and side- ■ Treatment with eluxadoline costs £88.20 per month. effects. he initial management of irritable locally within the gastrointestinal tract, Tbowel syndrome (IBS) entails dietary slowing gastrointestinal transit, reducing and lifestyle change and treatment with urgency and improving stool consistency; antispasmodic agents.1 For people with its abuse potential is low. IBS and diarrhoea, loperamide is the anti- Eluxadoline is licensed for the treat- motility agent of first choice, adjusting the ment of IBS with diarrhoea in adults. The dose to achieve optimum stool consist- recommended dosage is 100mg twice ency. If this is unsatisfactory, treatment daily (reduced to 75mg twice daily if with a low-dose tricyclic antidepressant poorly tolerated). Treatment should be should be considered, with an SSRI a initiated at the lower dose in older people further option if this is unsuccessful.
    [Show full text]
  • RELISTOR, INN: Methylnaltrexone Bromide
    The European Medicines Agency Evaluation of Medicines for Human Use EMEA/CHMP/10906/2008 ASSESSMENT REPORT FOR RELISTOR International Nonproprietary Name: METHYLNALTREXONE BROMIDE Procedure No. EMEA/H/C/870 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 8613 E-mail: [email protected] http://www.emea.eu.int TABLE OF CONTENTS Page 1 BACKGROUND INFORMATION ON THE PROCEDURE......................................... 3 1.1 Submission of the dossier ...................................................................................................... 3 1.2 Steps taken for the assessment of the product ....................................................................... 3 2 SCIENTIFIC DISCUSSION............................................................................................... 4 2.1 Introduction............................................................................................................................ 4 2.2 Quality aspects....................................................................................................................... 5 2.3 Non-clinical aspects............................................................................................................... 7 2.4 Clinical aspects .................................................................................................................... 13 2.5 Pharmacovigilance...............................................................................................................41
    [Show full text]
  • FDA Warns About an Increased Risk of Serious Pancreatitis with Irritable Bowel Drug Viberzi (Eluxadoline) in Patients Without a Gallbladder
    FDA warns about an increased risk of serious pancreatitis with irritable bowel drug Viberzi (eluxadoline) in patients without a gallbladder Safety Announcement [03-15-2017] The U.S. Food and Drug Administration (FDA) is warning that Viberzi (eluxadoline), a medicine used to treat irritable bowel syndrome with diarrhea (IBS-D), should not be used in patients who do not have a gallbladder. An FDA review found these patients have an increased risk of developing serious pancreatitis that could result in hospitalization or death. Pancreatitis may be caused by spasm of a certain digestive system muscle in the small intestine. As a result, we are working with the Viberzi manufacturer, Allergan, to address these safety concerns. Patients should talk to your health care professional about how to control your symptoms of irritable bowel syndrome with diarrhea (IBS-D), particularly if you do not have a gallbladder. The gallbladder is an organ that stores bile, one of the body’s digestive juices that helps in the digestion of fat. Stop taking Viberzi right away and get emergency medical care if you develop new or worsening stomach-area or abdomen pain, or pain in the upper right side of your stomach-area or abdomen that may move to your back or shoulder. This pain may occur with nausea and vomiting. These may be symptoms of pancreatitis, an inflammation of the pancreas, an organ important in digestion; or spasm of the sphincter of Oddi, a muscular valve in the small intestine that controls the flow of digestive juices to the gut. Health care professionals should not prescribe Viberzi in patients who do not have a gallbladder and should consider alternative treatment options in these patients.
    [Show full text]
  • Albany-Molecular-Research-Regulatory
    PRODUCT CATALOGUE API COMMERCIAL US EU Japan US EU Japan API Name Site CEP India API Name Site CEP India DMF DMF DMF DMF DMF DMF A Abiraterone Malta • Benztropine Mesylate Cedarburg • Adenosine Rozzano - Quinto de' Stampi • • * Betaine Citrate Anhydrous Bon Encontre • Betametasone-17,21- Alcaftadine Spain Spain • • Dipropionate Sterile • Alclometasone-17, 21- Spain Betamethasone Acetate Spain Dipropionate • • Altrenogest Spain • • Betamethasone Base Spain Amphetamine Aspartate Rensselaer Betamethasone Benzoate Spain * Monohydrate Milled • Betamethasone Valerate Amphetamine Sulfate Rensselaer Spain * • Acetate Betamethasone-17,21- Argatroban Rozzano - Quinto de' Stampi Spain • • Dipropionate • • • Atenolol India • • Betamethasone-17-Valerate Spain • • Betamethasone-21- Atracurium Besylate Rozzano - Quinto de' Stampi Spain • Phosphate Disodium Salt • • Bromfenac Monosodium Atropine Sulfate Cedarburg Lodi * • Salt Sesquihydrate • • Azanidazole Lodi Bromocriptine Mesylate Rozzano - Quinto de' Stampi • • • • • Azelastine HCl Rozzano - Quinto de' Stampi • • Budesonide Spain • • Aztreonam Rozzano - Valle Ambrosia • • Budesonide Sterile Spain • • B Bamifylline HCl Bon Encontre • Butorphanol Tartrate Cedarburg • Beclomethasone-17, 21- Spain Capecitabine Lodi Dipropionate • C • 2 *Please contact our Accounts Managers in case you are interested in this API. 3 PRODUCT CATALOGUE API COMMERCIAL US EU Japan US EU Japan API Name Site CEP India API Name Site CEP India DMF DMF DMF DMF DMF DMF Dexamethasone-17,21- Carbimazole Bon Encontre Spain • Dipropionate
    [Show full text]
  • Design and Synthesis of Cyclic Analogs of the Kappa Opioid Receptor Antagonist Arodyn
    Design and synthesis of cyclic analogs of the kappa opioid receptor antagonist arodyn By © 2018 Solomon Aguta Gisemba Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. Chair: Dr. Blake Peterson Co-Chair: Dr. Jane Aldrich Dr. Michael Rafferty Dr. Teruna Siahaan Dr. Thomas Tolbert Date Defended: 18 April 2018 The dissertation committee for Solomon Aguta Gisemba certifies that this is the approved version of the following dissertation: Design and synthesis of cyclic analogs of the kappa opioid receptor antagonist arodyn Chair: Dr. Blake Peterson Co-Chair: Dr. Jane Aldrich Date Approved: 10 June 2018 ii Abstract Opioid receptors are important therapeutic targets for mood disorders and pain. Kappa opioid receptor (KOR) antagonists have recently shown potential for treating drug addiction and 1,2,3 4 8 depression. Arodyn (Ac[Phe ,Arg ,D-Ala ]Dyn A(1-11)-NH2), an acetylated dynorphin A (Dyn A) analog, has demonstrated potent and selective KOR antagonism, but can be rapidly metabolized by proteases. Cyclization of arodyn could enhance metabolic stability and potentially stabilize the bioactive conformation to give potent and selective analogs. Accordingly, novel cyclization strategies utilizing ring closing metathesis (RCM) were pursued. However, side reactions involving olefin isomerization of O-allyl groups limited the scope of the RCM reactions, and their use to explore structure-activity relationships of aromatic residues. Here we developed synthetic methodology in a model dipeptide study to facilitate RCM involving Tyr(All) residues. Optimized conditions that included microwave heating and the use of isomerization suppressants were applied to the synthesis of cyclic arodyn analogs.
    [Show full text]
  • Current Awareness in Clinical Toxicology Editors: Damian Ballam Msc and Allister Vale MD
    Current Awareness in Clinical Toxicology Editors: Damian Ballam MSc and Allister Vale MD February 2016 CONTENTS General Toxicology 9 Metals 38 Management 21 Pesticides 41 Drugs 23 Chemical Warfare 42 Chemical Incidents & 32 Plants 43 Pollution Chemicals 33 Animals 43 CURRENT AWARENESS PAPERS OF THE MONTH How toxic is ibogaine? Litjens RPW, Brunt TM. Clin Toxicol 2016; online early: doi: 10.3109/15563650.2016.1138226: Context Ibogaine is a psychoactive indole alkaloid found in the African rainforest shrub Tabernanthe Iboga. It is unlicensed but used in the treatment of drug and alcohol addiction. However, reports of ibogaine's toxicity are cause for concern. Objectives To review ibogaine's pharmacokinetics and pharmacodynamics, mechanisms of action and reported toxicity. Methods A search of the literature available on PubMed was done, using the keywords "ibogaine" and "noribogaine". The search criteria were "mechanism of action", "pharmacokinetics", "pharmacodynamics", "neurotransmitters", "toxicology", "toxicity", "cardiac", "neurotoxic", "human data", "animal data", "addiction", "anti-addictive", "withdrawal", "death" and "fatalities". The searches identified 382 unique references, of which 156 involved human data. Further research revealed 14 detailed toxicological case reports. Current Awareness in Clinical Toxicology is produced monthly for the American Academy of Clinical Toxicology by the Birmingham Unit of the UK National Poisons Information Service, with contributions from the Cardiff, Edinburgh, and Newcastle Units. The NPIS is commissioned by Public Health England Current Awareness in Clinical Toxicology Editors: Damian Ballam MSc and Allister Vale MD February 2016 Current Awareness in Clinical Toxicology is produced monthly for the American Academy of Clinical Toxicology by the Birmingham Unit of the UK National Poisons Information Service, with contributions from the Cardiff, Edinburgh, and Newcastle Units.
    [Show full text]
  • A Review of Unique Opioids and Their Conversions
    A Review of Unique Opioids and Their Conversions Jacqueline Cleary, PharmD, BCACP Assistant Professor Albany College of Pharmacy and Health Sciences Adjunct Professor SAGE College of Nursing DISCLOSURES • Kaleo • Remitigate, LLC OBJECTIVES • Compare and contrast unique pharmacotherapy options for the treatment of chronic pain including: methadone, buprenoprhine, tapentadol, and tramadol • Select methadone, buprenorphine, tapentadol, or tramadol based on patient specific factors • Apply appropriate opioid conversion strategies to unique opioids • Understand opioid overdose risk surrounding opioid conversions and the use of unique opioids UNIQUE OPIOIDS METHADONE, BUPRENORPHINE, TRAMADOL, TAPENTADOL METHADONE My favorite drug because….? METHADONE- INDICATIONS • FDA labeled indications – (1) chronic pain (2) detoxification Oral soluble tablets for suspension NOT indicated for chronic pain treatment • Initial inpatient detoxification of opioids by a licensed trained provider with methadone and supportive care is appropriate • Methadone maintenance provider must have special credentialing and training as required by state Outpatient prescription must be for pain ONLY and say “for pain” on RX • Continuation of methadone maintenance from outside provider while patient is inpatient for another condition is appropriate http://cdn.atforum.com/wp-content/uploads/SAMHSA-2015-Guidelines-for-OTPs.pdf MECHANISM OF ACTION • Potent µ-opioid agonist • NMDA receptor antagonist • Norepinephrine reuptake inhibitor • Serotonin reuptake inhibitor ADVERSE EVENTS
    [Show full text]
  • Title Page Behavioral Effects and CNS Levels of the Broadly
    JPET Fast Forward. Published on March 20, 2012 as DOI: 10.1124/jpet.112.193227 JPET FastThis article Forward. has not beenPublished copyedited on and Marchformatted. 20, The 2012 final version as DOI:10.1124/jpet.112.193227 may differ from this version. JPET #193227 Title Page Behavioral effects and CNS levels of the broadly available κ-agonist hallucinogen salvinorin A are affected by p-glycoprotein modulation in vivo Downloaded from jpet.aspetjournals.org Eduardo R. Butelman, Michael Caspers, Kimberly M. Lovell, Mary Jeanne Kreek, Thomas E. Prisinzano at ASPET Journals on September 28, 2021 The Rockefeller University, New York, NY 10024 (ERB, MJK), and Department of Medicinal Chemistry, University of Kansas School of Pharmacy, Lawrence, KS 66045 (MC, KML, TEP) 1 Copyright 2012 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on March 20, 2012 as DOI: 10.1124/jpet.112.193227 This article has not been copyedited and formatted. The final version may differ from this version. JPET #193227 Running Title Page a) Running Title: p-glycoprotein and salvinorin A effects b) Corresponding author: E.R. Butelman, The Rockefeller University (Box 171), 1230 York Ave, New York NY 10065. Downloaded from Phone: (212)327-8247 FAX: (212)327-8574 e-mail: [email protected] jpet.aspetjournals.org c) Number of text pages: 25 Number of Tables: 1 Number of Figure: 6 Number of References: 38 Number of words in the Abstract: 250 at ASPET Journals on September 28, 2021 Number of words in the Introduction: 423 Number of words in the Discussion: 668 d) Nonstandard abbreviations used in the paper: BBB: blood-brain barrier; p-gp: p-glycoprotein; PT: pre-treatment e) Recommended section assignment: Behavioral pharmacology 2 JPET Fast Forward.
    [Show full text]
  • Opioid Antagonists As Potential Therapeutics for Ischemic Stroke
    Progress in Neurobiology 182 (2019) 101679 Contents lists available at ScienceDirect Progress in Neurobiology journal homepage: www.elsevier.com/locate/pneurobio Perspective article Opioid antagonists as potential therapeutics for ischemic stroke T ⁎ ⁎ Nadia Peyraviana,b, Emre Dikicia,b, Sapna Deoa,b, Michal Toboreka,b, , Sylvia Daunerta,b,c, a Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, USA b Dr. JT Macdonald Foundation Biomedical Nanotechnology Institute of the University of Miami, USA c University of Miami Clinical and Translational Science Institute, USA ARTICLE INFO ABSTRACT Keywords: Chronic use of prescription opioids exacerbates risk and severity of ischemic stroke. Annually, 6 million people Ischemic stroke die from stroke worldwide and there are no neuroprotective or neurorestorative agents to improve stroke out- Opioid antagonist comes and promote recovery. Prescribed opioids such as morphine have been shown to alter tight junction Blood brain barrier protein expression, resulting in the disruption of the blood brain barrier (BBB), ultimately leading to stroke Neuroprotection pathogenesis. Consequently, protection of the BBB has been proposed as a therapeutic strategy for ischemic Naloxone stroke. This perspective addresses the deficiency in stroke pharmacological options and examines a novel ap- Naltrexone plication and repurposing of FDA-approved opioid antagonists as a prospective neuroprotective therapeutic strategy to minimize BBB damage, reduce stroke severity, and promote neural recovery. Future directions discuss potential drug design and delivery methods to enhance these novel therapeutic targets. 1. Introduction modulate resulting microglia and macrophage activation in the is- chemic region to reduce neuroinflammation and prevent secondary As of 2017, the US government declared the opioid epidemic as a neurodegeneration resulting from phagocytosis of viable neurons.
    [Show full text]
  • Biased Signaling by Endogenous Opioid Peptides
    Biased signaling by endogenous opioid peptides Ivone Gomesa, Salvador Sierrab,1, Lindsay Lueptowc,1, Achla Guptaa,1, Shawn Goutyd, Elyssa B. Margolise, Brian M. Coxd, and Lakshmi A. Devia,2 aDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029; bDepartment of Physiology & Biophysics, Virginia Commonwealth University, Richmond, VA 23298; cSemel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA 90095; dDepartment of Pharmacology & Molecular Therapeutics, Uniformed Services University, Bethesda MD 20814; and eDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA 94143 Edited by Susan G. Amara, National Institutes of Health, Bethesda, MD, and approved April 14, 2020 (received for review January 20, 2020) Opioids, such as morphine and fentanyl, are widely used for the possibility that endogenous opioid peptides could vary in this treatment of severe pain; however, prolonged treatment with manner as well (13). these drugs leads to the development of tolerance and can lead to For opioid receptors, studies showed that mice lacking opioid use disorder. The “Opioid Epidemic” has generated a drive β-arrestin2 exhibited enhanced and prolonged morphine-mediated for a deeper understanding of the fundamental signaling mecha- antinociception, and a reduction in side-effects, such as devel- nisms of opioid receptors. It is generally thought that the three opment of tolerance and acute constipation (15, 16). This led to types of opioid receptors (μ, δ, κ) are activated by endogenous studies examining whether μOR agonists exhibit biased signaling peptides derived from three different precursors: Proopiomelano- (17–20), and to the identification of agonists that preferentially cortin, proenkephalin, and prodynorphin.
    [Show full text]
  • BBC Program 2016.Pages
    March 5-6, 2016 La Quinta Inn & Suites Medical Center San Antonio, TX Behavior, Biology, and Chemistry: Translational Research in Addiction BBC 2016 BBC Publications BBC 2011 Stockton Jr SD and Devi LA (2012) Functional relevance of μ–δ opioid receptor heteromerization: A Role in novel signaling and implications for the treatment of addiction disorders: From a symposium on new concepts in mu-opioid pharmacology. Drug and Alcohol Dependence Mar 1;121(3):167-72. doi: 10.1016/j.drugalcdep.2011.10.025. Epub 2011 Nov 23 Traynor J (2012) μ-Opioid receptors and regulators of G protein signaling (RGS) proteins: From a sym- posium on new concepts in mu-opioid pharmacology. Drug and Alcohol Dependence Mar 1;121(3): 173-80. doi: 10.1016/j.drugalcdep.2011.10.027. Epub 2011 Nov 29 Lamb K, Tidgewell K, Simpson DS, Bohn LM and Prisinzano TE (2012) Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: New concepts in mu opioid receptor pharmacology: From a symposium on new concepts in mu-opioid pharma- cology. Drug and Alcohol Dependence Mar 1;121(3):181-8. doi: 10.1016/j.drugalcdep.2011.10.026. Epub 2011 Nov 26 Whistler JL (2012) Examining the role of mu opioid receptor endocytosis in the beneficial and side-ef- fects of prolonged opioid use: From a symposium on new concepts in mu-opioid pharmacology. Drug and Alcohol Dependence Mar 1;121(3):189-204. doi: 10.1016/j.drugalcdep.2011.10.031. Epub 2012 Jan 9 BBC 2012 Zorrilla EP, Heilig M, de Wit, H and Shaham Y (2013) Behavioral, biological, and chemical perspectives on targeting CRF1 receptor antagonists to treat alcoholism.
    [Show full text]